Eli Lilly and Company (LLY)

NYSE: LLY · Real-Time Price · USD
790.65
+3.73 (0.47%)
At close: Jul 10, 2025, 4:00 PM
786.00
-4.65 (-0.59%)
Pre-market: Jul 11, 2025, 9:18 AM EDT
0.47%
Market Cap 709.79B
Revenue (ttm) 49.00B
Net Income (ttm) 11.11B
Shares Out 897.74M
EPS (ttm) 12.29
PE Ratio 64.33
Forward PE 31.42
Dividend $6.00 (0.76%)
Ex-Dividend Date Aug 15, 2025
Volume 3,131,256
Open 789.67
Previous Close 786.92
Day's Range 786.43 - 799.49
52-Week Range 677.09 - 972.53
Beta 0.40
Analysts Strong Buy
Price Target 1,015.65 (+28.46%)
Earnings Date Aug 7, 2025

About LLY

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals in the United States, Europe, China, Japan, and internationally. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It also provides oncology products, including Alimta, Cyramza, Erbitux, Ja... [Read more]

Sector Healthcare
Founded 1876
Employees 47,000
Stock Exchange NYSE
Ticker Symbol LLY
Full Company Profile

Financial Performance

In 2024, Eli Lilly's revenue was $45.04 billion, an increase of 32.00% compared to the previous year's $34.12 billion. Earnings were $10.59 billion, an increase of 102.08%.

Financial Statements

Analyst Summary

According to 17 analysts, the average rating for LLY stock is "Strong Buy." The 12-month stock price target is $1,015.65, which is an increase of 28.46% from the latest price.

Price Target
$1,015.65
(28.46% upside)
Analyst Consensus: Strong Buy
Stock Forecasts

News

Eli Lilly Comes Out As ADA Winner

Eli Lilly reported impressive data from bimagrumab and eloralintide programs, reinforcing its leadership in obesity therapeutics. Results from competitors were either as expected or underwhelming. Fav...

16 hours ago - Seeking Alpha

The Big 3: AVGO, LLY, UBER

Joe Tigay joins today's Big 3 and turns to three stocks that he believes investors should keep on their radar as the market "broadens." He talks about the potential for Broadcom (AVGO) to continue its...

Other symbols: AVGOUBER
20 hours ago - Schwab Network

Zepbound Powers Eli Lilly's Upbeat Q2 Outlook

Eli Lilly and Co. LLY is set to release its second-quarter earnings on August 7. According to Benzinga Pro data, analysts are anticipating adjusted earnings of $5.56 per share and sales of $14.4 billi...

1 day ago - Benzinga

US FDA approves gradual dosing for Lilly Alzheimer's drug

The U.S. Food and Drug Administration approved changing the prescribing information for Eli Lilly's Alzheimer's drug Kisunla to allow more gradual dosing to lower the risk of a potentially dangerous t...

2 days ago - Reuters

FDA approves updated label for Lilly's Kisunla (donanemab-azbt) with new dosing in early symptomatic Alzheimer's disease

The newly recommended dosing schedule significantly lowered ARIA-E rates compared to the original dosing schedule, adding to the established safety profile of the treatment INDIANAPOLIS , July 9, 2025...

2 days ago - PRNewsWire

Trump threatens impose up to 200% tariff on pharmaceuticals 'very soon'

President Donald Trump threatened to impose up to 200% tariffs on pharmaceuticals imported into the U.S. "very soon."  But he suggested that those levies would not go into effect immediately, saying h...

Other symbols: ABBVJNJ
2 days ago - CNBC

Demand for obesity drugs shoots up in India as Lilly, Novo jostle for market share

Demand for weight-loss drugs is rising at a fast clip in India where rivals Eli Lilly and Novo Nordisk are competing for market share, data from research firm Pharmarack showed on Monday.

4 days ago - Reuters

Eli Lilly's 3-step strategy to dominate the $95 billion obesity market

Eli Lilly has outpaced Ozempic-maker Novo Nordisk in the race to develop new incretin drugs. The company is set to capture 50% of the $95 billion obesity market by 2050.

4 days ago - Business Insider

Lilly and Novo Are the Kings of Weight-Loss Drugs. The Companies Coming for Their Crowns.

Both well-established and small, clinical-stage pharma companies are investing heavily to be able to someday compete with Lilly and Novo.

7 days ago - Barrons

Top 50 High-Quality Dividend Stocks For July 2025

I track 50 high-quality dividend growth stocks to identify opportune investments, updating valuation ratings daily to focus on attractive opportunities. In this turbulent year, my investable universe ...

9 days ago - Seeking Alpha

Top 15 High-Growth Dividend Stocks For July 2025

My Top 15 High-Growth Dividend Stocks outperformed SPY and VIG in June, gaining 6.15% versus SPY's 5.14% and VIG's 3.41%. The list's year-to-date return is 12.59%, beating SPY every month in 2025, tho...

Other symbols: APHBACBKDKSDPZELVGPN
9 days ago - Seeking Alpha

CVS drops Lilly's Zepbound

CNBC's Angelica Peebles reports on news regarding CVS.

Other symbols: CVS
9 days ago - CNBC Television

Eli Lilly seen as the stronger bet amid escalating competition with Novo in India

The global fight between Eli Lilly and Novo Nordisk for dominance in the red-hot weight-loss drug market is shifting to India, one of the fastest-growing pharmaceutical frontiers. As rising obesity an...

15 days ago - Invezz

Lilly to launch Mounjaro pen in India to compete with Novo's Wegovy

Eli Lilly said on Thursday India's drug regulator had approved the launch of pre-filled injector pens of its blockbuster weight-loss drug, Mounjaro, giving it more options to compete with Novo Nordisk...

Other symbols: NVO
15 days ago - Reuters

Buy Eli Lilly While The Market Hesitates And Let Time Make You Dominate

Eli Lilly is positioned for a 30-50% return in the next 12 months based on a nexus of value and growth. While others hesitate on greatness, I buy at the prices everyone else wishes they did. Risks are...

15 days ago - Seeking Alpha

Weight loss and diabetes jabs linked to potentially fatal side effect

Weight loss and diabetes jabs taken by more than a million people in the UK have been linked to a potential serious side effect, with some deaths, according to data from the UK medicines regulator.

Other symbols: NVO
15 days ago - Skynews

Healthy Returns: New weight loss drug data show Eli Lilly is gaining ground

Eli Lilly, Novo Nordisk and Amgen release weight loss drug data as competition heats up in the market, while Abridge announces a $300 million funding round.

15 days ago - CNBC

Eli Lilly: It Is A Bet On Human Longevity

Eli Lilly's recent stock dip creates a compelling buying opportunity, with its valuation multiples falling to 2022 levels, despite explosive growth prospects and a deep, innovative product pipeline. D...

17 days ago - Seeking Alpha

Pharma companies need to beef up M&A right now, says Mizuho's Jared Holz

Jared Holxz, Mizuho, joins 'Fast Money' to talk competition in the obesity drug space.

17 days ago - CNBC Television

Lilly declares third-quarter 2025 dividend

INDIANAPOLIS , June 23, 2025 /PRNewswire/ -- The board of directors of Eli Lilly and Company (NYSE: LLY) has declared a dividend for the third quarter of 2025 of $1.50 per share on outstanding common ...

17 days ago - PRNewsWire

Eli Lilly and Company (LLY) Presents at Special Call (Lilly Investor Event at American Diabetes Association's (ADA) 85th Scientific Sessions) Conference Transcript

Eli Lilly and Company (NYSE:LLY) Special Call (Lilly Investor Event at American Diabetes Association's (ADA) 85th Scientific Sessions) Conference June 22, 2025 7:30 PM ET Company Participants Jeffrey...

18 days ago - Seeking Alpha

Lilly's once-weekly insulin efsitora alfa demonstrated A1C reduction and a safety profile consistent with daily insulin in multiple Phase 3 trials

Results from the fixed-dose QWINT-1 study, along with the QWINT-3 and QWINT-4 studies, reinforce efsitora's potential to simplify insulin management with weekly dosing Lilly plans to submit efsitora f...

18 days ago - PRNewsWire

Lilly expects orforglipron obesity results in third quarter

Eli Lilly said on Saturday its experimental pill orforglipron helped diabetics lose weight and lower their blood sugar, and the company aims to announce in the third quarter trial results for the drug...

20 days ago - Reuters

Lilly's oral GLP-1, orforglipron, showed compelling efficacy and a safety profile consistent with injectable GLP-1 medicines, in complete Phase 3 results published in The New England Journal of Medicine

The investigational once-daily pill  lowered A1C by an average of 1.3% to 1.6% across doses, with improvements seen as early as four weeks, in adults with type 2 diabetes  In ACHIEVE-1, orforglipron a...

20 days ago - PRNewsWire

Final Trade: LLY, SHEL, USO, WMT

The final trades of the day with the Fast Money traders.

Other symbols: WMTSHELUSO
20 days ago - CNBC Television